Cote R H
1Department of Biochemistry and Molecular Biology, University of New Hampshire, Durham, NH 03824-2617, USA.
Int J Impot Res. 2004 Jun;16 Suppl 1:S28-33. doi: 10.1038/sj.ijir.3901212.
Phosphodiesterase 6 (PDE6) is highly concentrated in the retina. It is most abundant in the internal membranes of retinal photoreceptors, where it reduces cytoplasmic levels of cyclic guanosine monophosphate (cGMP) in rod and cone outer segments in response to light. The rod PDE6 holoenzyme comprises alpha and beta catalytic subunits and two identical inhibitory gamma subunits. Each catalytic subunit contains three distinct globular domains corresponding to the catalytic domain and two GAF domains (responsible for allosteric cGMP binding). The PDE6 catalytic subunits resemble PDE5 in amino-acid sequence as well as in three-dimensional structure of the catalytic dimer; preference for cGMP over cyclic adenosine monophosphate (cAMP) as a substrate; and the ability to bind cGMP at the regulatory GAF domains. Most PDE5 inhibitors inhibit PDE6 with similar potency, and electroretinogram studies show modest effects of PDE5 inhibitors on visual function-an observation potentially important in designing PDE5-specific therapeutic agents.
磷酸二酯酶6(PDE6)高度集中于视网膜。它在视网膜光感受器的内膜中含量最为丰富,在那里,它会响应光线降低视杆和视锥细胞外段细胞质中的环鸟苷单磷酸(cGMP)水平。视杆细胞PDE6全酶由α和β催化亚基以及两个相同的抑制性γ亚基组成。每个催化亚基包含三个不同的球状结构域,分别对应催化结构域和两个GAF结构域(负责变构cGMP结合)。PDE6催化亚基在氨基酸序列以及催化二聚体的三维结构上类似于PDE5;作为底物时对cGMP的偏好超过环磷酸腺苷(cAMP);以及在调节性GAF结构域结合cGMP的能力。大多数PDE5抑制剂以相似的效力抑制PDE6,视网膜电图研究表明PDE5抑制剂对视觉功能有适度影响——这一观察结果在设计PDE5特异性治疗药物方面可能具有重要意义。